



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Efdamrofusp alfa

<b>Cat. No.:</b>	HY-P99905
<b>CAS No.:</b>	2375661-82-6
<b>Target:</b>	VEGFR
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions <sup>[1]</sup> .								
<b>In Vitro</b>	<p>Efdamrofusp alfa (0.135 mg/mL; 0, 6, 12, or 24 h) suppresses endothelial cell migration and tube formation<sup>[1]</sup>.  Efdamrofusp alfa (0-1000 µg/mL) inhibits complement activation in vitro<sup>[1]</sup>.  MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Migration Assay <sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human primary umbilical vein endothelial cell (HUVEC)</td> </tr> <tr> <td>Concentration:</td> <td>0.135 mg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>0, 6, 12, or 24 h</td> </tr> <tr> <td>Result:</td> <td>Showed a 20.91% reduction in migration.</td> </tr> </table>	Cell Line:	Human primary umbilical vein endothelial cell (HUVEC)	Concentration:	0.135 mg/mL	Incubation Time:	0, 6, 12, or 24 h	Result:	Showed a 20.91% reduction in migration.
Cell Line:	Human primary umbilical vein endothelial cell (HUVEC)								
Concentration:	0.135 mg/mL								
Incubation Time:	0, 6, 12, or 24 h								
Result:	Showed a 20.91% reduction in migration.								
<b>In Vivo</b>	<p>Efdamrofusp alfa (13.5 µg; 3 days) inhibits activation of the complement system in a mouse model of laser-induced CNV<sup>[1]</sup>.  Efdamrofusp alfa (1.35 mg; single intravitreal injection) shows favorable safety profiles and exhibited antiangiogenic efficacy in a nonhuman primate laser-induced CNV model<sup>[1]</sup>.  MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6J mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>13.5 µg; 13.0 µg</td> </tr> <tr> <td>Administration:</td> <td>3 days; 7 days</td> </tr> <tr> <td>Result:</td> <td>           Significantly reduced C3d deposition.            Reduced vascular leakage at 7 days after laser-induced injury.            Significantly suppressed CNV formation 7 days after laser-induced injury.            Reduced the concentrations of vitreous VEGF-A.         </td> </tr> </table>	Animal Model:	C57BL/6J mice <sup>[1]</sup>	Dosage:	13.5 µg; 13.0 µg	Administration:	3 days; 7 days	Result:	Significantly reduced C3d deposition. Reduced vascular leakage at 7 days after laser-induced injury. Significantly suppressed CNV formation 7 days after laser-induced injury. Reduced the concentrations of vitreous VEGF-A.
Animal Model:	C57BL/6J mice <sup>[1]</sup>								
Dosage:	13.5 µg; 13.0 µg								
Administration:	3 days; 7 days								
Result:	Significantly reduced C3d deposition. Reduced vascular leakage at 7 days after laser-induced injury. Significantly suppressed CNV formation 7 days after laser-induced injury. Reduced the concentrations of vitreous VEGF-A.								

---

Animal Model:	Rhesus monkeys <sup>[1]</sup>
Dosage:	1.35 mg
Administration:	Single intravitreal injection
Result:	Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days.

---

## REFERENCES

---

[1]. Shiqi Yang, et al. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. *Sci Transl Med.* 2022 Jun;14(647):eabj2177.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA